Company: OPGN
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001829126-25-009312
Chunk: 73

Company: OPGEN INC
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 8
Chunk 73
---
, Cost of Services, and Operating Expenses

Prior to the repositioning of our business, our cost of products consisted of product and inventory costs, including materials costs and overhead, and other costs related to the recognition of revenue. Cost of services related to the material and labor costs associated with providing our services. Research and development expenses consisted primarily of expenses incurred in connection with our clinical and pre-clinical research activities. Selling, general and administrative expenses consisted of public company costs, salaries, and related costs for administrative, sales, and business development personnel.

Following the acquisition of a controlling interest in the Company by AEI Capital Ltd. and the formation of CapForce as OpGen’s wholly-owned subsidiary, the Company’s cost of sales will primarily be subcontractor and advisor fees and technology infrastructure costs associated with providing our services. Research and development expenses consist of fees to expand and innovate CapForce’s digital investment banking platform, and selling, general, and administrative expenses continue to consist of public company costs, salaries, and related costs for administrative and business development purposes.

24

Results of operations for the three months ended September 30, 2025 and 2024

Revenues

We did not generate any revenues in the three months ended September 30, 2025 and 2024.

Operating expenses

    Three Months Ended September 30,

    2025

    2024

    Cost of products sold
     
    $
    -

    $
    -

    Cost of services

    -

    -

    Research and development

    -

    488

    General and administrative

    701,915

    768,551

    Sales and marketing

    270

    14,846

    Total operating expenses
     
    $
    702,185

    $
    783,885

Our total operating expenses for the three months ended September 30, 2025 decreased approximately 10% when compared to the same period in 2024. Operating expenses changed as follows:

    ●
    Cost of products sold and cost of services: we had no cost of products sold or cost of services for the three months ended September 30, 2025 and 2024 as we had no products sales or laboratory services in those periods due to the Company scaling down its legacy operations and repositioning its business; and

    ●
    Research and development, general and administrative, and sales and marketing: research and development, general and administrative, and sales and marketing expenses decreased approximately